Patents Assigned to Institut National de la Sante et de la Recherche Medicale
  • Patent number: 10463713
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of viral infection.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: November 5, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT-PARIS 7, INSTITUT PASTEUR
    Inventors: Jean-Luc Poyet, Asier Saez-Cirion, Heriberto Bruzzoni-Giovanelli, Leonard Jagot-Lacoussiere, Annie David, Anastassia Mikhailova
  • Publication number: 20190330286
    Abstract: Embodiments of the present disclosure relate to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of: a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, and b) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).
    Type: Application
    Filed: January 12, 2018
    Publication date: October 31, 2019
    Applicants: INSTITUT NATIONAL UNIVERSITAIRE JEAN-FRANCOIS CHAMPOLLION, UNIVERSITE TOULOUSE III - PAUL SABATIER, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE ROUEN-NORMANDIE
    Inventors: Khaddouj Benmoussa, Elsa Bonnafe, Agnès Coste, Jérôme Leprince, Bernard Pipy, Michel Treilhou
  • Patent number: 10457678
    Abstract: The present invention relates to new N1- and N7-substituted sibiriline derivatives of the following general formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as drug, in particular for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising such a compound and processes to prepare such a compound. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 29, 2019
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Universite Claude Bernard Lyon 1
    Inventors: Marie-Thérèse Dimanche-Boitrel, Stéphane Bach, Claire Delehouze, Peter Goekjian, Arnaud Comte
  • Patent number: 10440947
    Abstract: The present invention relates to an aqueous solution for organ preservation, in particular for the myocardium, the solution comprising: 100 mM to 130 mM of Na+; 12 mM to 15 mM of K+; 0.25 mM to 1.3 mM of Ca++; 0.5 ?M to 1.5 ?M of cyclosporin A; and 0.5 ?M to 1.5 ?M of taxol, and it also relates to the joint use of cyclosporin A and taxol in a solution for in vitro preservation of an organ, in particular the myocardium.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: October 15, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD LYON I
    Inventor: Rene Ferrera
  • Publication number: 20190307738
    Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: June 13, 2017
    Publication date: October 10, 2019
    Applicants: Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Universite Paris SUD, Assistance Publique-Hopitaux de Paris (APHP), Hopital Marie Lannelongue
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Patent number: 10435744
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 8, 2019
    Assignees: BIO-RAD EUROPE GMBH, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
  • Patent number: 10436686
    Abstract: The invention relates to a method of separating biological particles from the liquid containing same for purification, analysis and optionally diagnostic purposes. The inventive method comprises at least one step involving vertical filtration through a filter having a porosity that is adapted to the type of biological particles to be separated, such that said particles are retained by the filter. The invention is characterised in that: (i) the method involves the use of a filter comprising at least one basic filtration zone, whereby each basic filtration zone has a limited surface area; and (ii) the surface area of each basic filtration zone and the number of basic filtration zones are selected as a function of the type of liquid to be filtered, the type of biological particles to be separated and the volume of liquid to be filtered.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: October 8, 2019
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE RENE DESCARTES-PARIS V
    Inventor: Patrizia Paterlini-Brechot
  • Publication number: 20190298691
    Abstract: The present invention relates to FLT3 receptor inhibitor for use in the treatment of neuropathic pain and chronic pain comprising a neuropathic component, wherein the daily dosage range per human adult per day of said FLT3 receptor inhibitor consists of a dosage range determined by a method comprising the steps of: (i) determining the minimal inhibiting dose of said FLT3 receptor inhibitor that induces the maximal inhibition of mechanical pain hypersensitivity, (ii) converting said dose to the Human Equivalent Dose (HED) by the allometric correction method, and (iii) establishing a daily dosage range per human adult per day wherein (iii-1) the lower limit of the said daily dosage range per human adult per day is the greater value between HED/20 determined via a rat model and 0.001 mg, and (iii-2) the upper limit of the said daily dosage range is the lower value between HED*20 determined via a rat model and 50 mg.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 3, 2019
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER, BIODOL THERAPEUTICS
    Inventor: Jean VALMIER
  • Patent number: 10426818
    Abstract: The present invention relates to an APJ receptor agonist for use in the treatment or the prevention of diabetes.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: October 1, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paul Sabatier Toulouse, Centre Hospitalier Universitaire de Toulouse
    Inventors: Philippe Valet, Isabelle Laurell, Laurent Cazals, Pierre Gourdy
  • Patent number: 10426816
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: October 1, 2019
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Pasteur de Lille
    Inventors: Jean-Claude Sirard, Jose A. Chabalgoity
  • Patent number: 10426758
    Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 1, 2019
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De Poitiers, Sorbonne Universite, Universite Claude Bernard Lyon 1
    Inventors: Marie-Thérèse Dimanche-Boitrel, Stéphane Bach, Claire Delehouze, Yvette Mettey, Peter Goekjian, Arnaud Comte
  • Patent number: 10420827
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 24, 2019
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille, National University of Ireland Maynooth
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanaugh
  • Patent number: 10423017
    Abstract: Method for determining the characteristics of a system for generating at least one pattern of light, the method comprising: a) providing a desired pattern of light, b) expressing the amplitude and the phase of the output pulse of the system as a function of the input laser pulse and in function of the characteristics of the system to obtain a calculated output pulse, the input laser pulse having a duration below or equal to 1 nanosecond, c) determining at least one characteristic of the system by minimizing a distance between the calculated output pulse and the desired output laser pulse.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: September 24, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE
    Inventors: Jean-Francois Leger, Laurent Bourdieu, Stephane Dieudonne
  • Patent number: 10407500
    Abstract: The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: September 10, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Didrerot—Paris 7
    Inventors: Anne Joutel, Søren Christensen, Thorleif Jan Pedersen
  • Patent number: 10407695
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 10, 2019
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aude Sirven, Anne Dubart Kupperschmitt
  • Patent number: 10407667
    Abstract: The present invention relates to a method for rapid generation of an infectious RNA virus that completely eliminates the need of constructing a full-length c DNA, which covers the entire viral genome, cloning and propagating such full length c DNA.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: September 10, 2019
    Assignees: UNIVERSITÉ D'AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Fabien Aubry, Antoine Nougairéde, Gilles Quérat, Xavier De Lamballerie, Ernest Andrew Gould, Lauriane De Fabritus
  • Patent number: 10400284
    Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: September 3, 2019
    Assignees: INTEGRAGEN, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
    Inventors: Thomas Rio Frio, Pierre Laurent-Puig, Sandrine Imbeaud
  • Patent number: 10401567
    Abstract: An optical fiber mode scrambler adapted to give a determined bending to an optical fiber inserted in the mode scrambler, the mode scrambler having a general extension direction X, the mode scrambler having a morphology adapted to give the optical fiber a direction along X at the entry of the scrambler, and then to bend the fiber to bring the fiber substantially in the X, Y plan in the ?X and Y directions, before bringing the fiber in a rotation around the X axis substantially in the Y, Z plan in the anti clockwise direction for one full rotation, and then bending the fiber to bring the fiber substantially in the X, Y plan in the ?X and ?Y directions, and then bending the fiber to give the optical fiber a direction along X at the exit of the scrambler.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: September 3, 2019
    Assignees: INSERM ( INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ DE LILLE, CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
    Inventors: Serge Mordon, Pascal Delepôrte, Nacim Betrouni
  • Patent number: 10398774
    Abstract: The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: September 3, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Bruno Robert, Christel Larbouret, Pierre Martineau, Marie-Alix Poul
  • Patent number: 10394010
    Abstract: An optical system for shaping a wavefront of an electric field of an input light beam to be projected into a target volume including a first optical element, a spatial light modulator used to control light distribution in at least one transverse plane in the target volume. An intermediate optical element located on an optical axis, after the first optical element on a trajectory of the light beam for modulating the phase or the amplitude of the electric field of the input light beam is included. A second optical element for modulating the phase or the amplitude of the electric field of the input light beam is used to control the axial position of the transverse plane in the target volume. The second optical element is situated on the optical axis after the at least one intermediate optical element on the trajectory of the light beam.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: August 27, 2019
    Assignees: UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE(INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Oscar Hernandez-Cubero, Eirini Papagiakoumou, Emiliani Valentina